Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neoplasms × Calcium Carbonate × Clear all

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia 2 Breast Neoplasms 2 Vitamin D Deficiency 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pain 1 Ovarian Neoplasms 1 Osteoporosis 1 Obesity 1 Neoplasms 1 Myelodysplastic Syndromes 1 Lymphoma 1 Colorectal Neoplasms 1 Arthralgia 1 Aflatoxin Poisoning 1

Interventions

Bevacizumab 45 Gemcitabine 44 Cyclophosphamide 39 Carboplatin 37 Docetaxel 34 Fluorouracil 32 Cisplatin 32 Paclitaxel 31 pembrolizumab 28 Oxaliplatin 25 Radiotherapy 24 Irinotecan 23 Leucovorin 22 Capecitabine 22 Dexamethasone 21 Cetuximab 21 Nivolumab 19 Pemetrexed 18 Drug Therapy 18 Doxorubicin 18 Erlotinib Hydrochloride 17 Trastuzumab 15 Rituximab 15 Prednisone 15 durvalumab 14 atezolizumab 13 Sorafenib 13 fludarabine 12 Lapatinib 12 Everolimus 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01677195 2016-04-19

RDMEACCS100

Texas Enterosorbents Incorporated

Phase 2 Completed

234 enrolled 7 charts

Aflatoxin Poisoning, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡